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Abstract: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease
that predominantly affects women in early to middle age. It is typically associated with autoantibodies to mitochondrial antigens and results in immune-mediated destruction of small and
medium-sized intrahepatic bile ducts leading to cholestasis, hepatic fibrosis and may progress to cirrhosis or hepatic failure and, in some cases, hepatocellular carcinoma. The clinical
presentation and the natural history of PBC have improved over the years due to recognition
of earlier widespread use of ursodeoxycholic acid (UDCA); about one-third of patients show
suboptimal biochemical response to UDCA with poor prognosis. Until recently, UDCA was
the only US Food and Drug Administration approved agent for this disease for more than
two decades; obeticholic acid was approved in 2016 for treatment of patients with PBC with
a suboptimal response or intolerance to UDCA. Currently, liver transplantation is the most
effective treatment modality for PBC patients with end-stage liver disease. This review will
focus on the recent advances in therapy of primary biliary cholangitis, with emphasis on
obeticholic acid.
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Primary biliary cholangitis (PBC) is a chronic, autoimmune, slowly progressive
cholestatic liver disease that predominantly affects middle-aged women at a ratio
of ~10:1 of women to men.1 Although the reason for this gender difference is not fully
understood, X chromosome monosomy is observed in women with PBC, and it has
been found that genes related to X-linked immunodeficiencies can lead to granuloma
formation and elevated immunoglobulin (Ig) M levels, a frequent observation in PBC.2
The worldwide prevalence rate of PBC is estimated to be between 67 and 940 cases
per million population and the incidence is between 0.7 and 49 cases per million
population per year.3 Human Development Index estimated that there is a positive
association between the incidence of PBC and socioeconomic status; moreover, the
incidence rate is low in developing countries.4 The prevalence rates of PBC are high
in UK, Scandinavia, Canada and USA.4
The exact pathogenesis of PBC remains unclear. However, there is compelling
evidence that the mechanism is likely related to a combination of genetic predisposition
and environmental factors,3,5 explaining the geographic variation as well as familial
occurrence of this disease. The immune-mediated destruction of bile duct epithelial
cells drives the pathogenesis of PBC.6,7 Persistent destruction of the bile ducts leads
to intrahepatic accumulation of cytotoxic bile acid, resulting in hepatocellular injury,
fibrosis and cirrhosis.8
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The diagnosis of PBC is confirmed by the presence of at
least two of the following three objective criteria: 1) biochemical evidence of intrahepatic cholestasis based on elevated
levels of alkaline phosphatase (ALKP) of $1.5 times the
upper limit of normal (ULN) for .24 weeks; 2) the presence
of serum titers of antimitochondrial antibodies (AMAs) of
more than or equal to 1:40; and 3) liver histology compatible with features of PBC, characterized by nonsuppurative
cholangitis and granulomatous destruction of interlobular
bile ducts with exclusion of drug-induced liver injury.8,9 The
disease usually presents with a cholestatic pattern of liver
test abnormalities (predominant elevation of serum ALKP,
out of proportion to elevation of serum aminotransferases
[alanine aminotransferase {ALT}, aspartate aminotransferase
{AST}]), and the vast majority of patients also have a positive serum AMA. AMAs are highly sensitive and specific,
usually present in 95% of patients and given 98% specificity,
liver biopsy is rarely required for the diagnosis of PBC.10
Liver biopsy is helpful in staging and if there is suspicion of
overlap syndromes (ie, with autoimmune hepatitis [AIH]) or
coexisting liver conditions (ie, nonalcoholic steatohepatitis,
drug-induced liver injury).11
Autoimmune liver diseases consist of PBC, primary
sclerosing cholangitis, AIH, and IgG4 sclerosing cholangitis.
In addition, some patients present with features of other autoimmune liver diseases and will be categorized into a separate
class called “overlap syndromes”.12–15 According to Paris
criteria,12,16,17 an AIH–PBC overlap syndrome is accepted
when two or three criteria of PBC as well as AIH are fulfilled.
For AIH, the criteria are:12 1) serum ALT level of $5 times
the ULN; 2) portal or periportal lymphocytic inflammation;
and 3) moderate to severe periportal lymphocytic piecemeal
necrosis. For PBC, the criteria are: 1) ALKP .2 times the
ULN or gamma-glutamyl transferase (GGT) .5 times
the ULN; 2) AMA positivity; and 3) florid duct lesions or
destructive cholangitis on histologic examinations. Kuiper
et al18 conducted a study on 134 patients of PBC–AIH overlap
syndrome. They found that the sensitivity and specificity of
Paris criteria for diagnosing overlap syndrome are 92% and
97%, respectively.
The associations between PBC and extrahepatic auto
immune diseases have been well established.19,20 More than
50% of patients with PBC have other autoimmune disease.
The extrahepatic autoimmune diseases that have been
associated with PBC are Sjogren’s syndrome, systemic
lupus erythematosus, rheumatoid arthritis, Raynaud’s disease, CREST syndrome, inflammatory bowel diseases and
insulin-dependent diabetes mellitus. Among these conditions,
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Sjogren’s syndrome and Raynaud’s disease are strongly
associated with PBC.20,21
The main aim in the management of PBC is to reverse
injury from bile duct inflammation, improve the symptoms, slow down the disease progression, improve liver
biochemistries, and prevent the long-term consequences of
chronic cholestasis, such as pruritus, fatigue, osteoporosis
and fat-soluble vitamin deficiencies.22 Since the introduction of hydrophilic bile acids such as ursodeoxycholic acid
(UDCA) and their widespread use, the clinical presentation
and progression of natural disease history of PBC patients
have improved significantly over the past two decades.23–25
However, about one-third of PBC patients show suboptimal
biochemical responses to UDCA and remain at risk for continued progression of disease to more advanced diseases,
including cirrhosis.26–28

Ursodeoxycholic acid
UDCA was the only drug approved by the US Food and Drug
Administration for the treatment of PBC until the approval
of obeticholic acid (OCA) in 2016.29 Chronic cholestasis will
result in intrahepatic and systemic accumulation of cytotoxic
bile acids that will initially promote hepatocyte proliferation but eventually lead to hepatocellular injury, apoptosis,
fibrosis and cirrhosis. UDCA has multiple mechanisms
of action in cholestatic conditions including protection of
cholangiocytes and periportal hepatocytes from the cytotoxic
effects of hydrophobic bile acids, stimulation of hepatocellular and ductular secretion of hydrophobic bile acids and
hepatocyte protection against bile acid–induced apoptosis.
UDCA also has additional anti-inflammatory and immunomodulatory effects.30
Administration of UDCA increases the bile acid saturation
in bile, resulting in increased bile acid clearance from blood
and reduced cholestatic symptoms, specifically pruritus.
These effects of UDCA occur with the optimal dose of
13–15 mg/kg/day, and it has been proposed to have choleretic
and anti-inflammatory effects. It shows improvement in liver
biochemistries, slows the histologic progression of the disease
and also improves overall survival, at least in those treated in
the early stages of the disease.31,32 ter Borg et al33 conducted
a prospective cohort study of 297 PBC patients and showed
that administration of UDCA in patients with early histologic
changes significantly improved transplant-free survival
(1 year =99.7%, 5 years =87% and 10 years =71%) than
that predicted by the Mayo model. Poupon et al34 conducted
a meta-analysis of French, Canadian and Mayo Clinical
trials and demonstrated that time to liver transplantation was
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significantly improved in patients with moderate to severe
disease (serum bilirubin level of $1.4 mg/dL, stage 3 and
4 histologic abnormalities).
PBC is a rare and slowly progressive disease, and therefore, in most cases, individual clinical trials lacked power to
demonstrate clinically significant differences in outcomes.
So, the rates of clinical outcomes in patients treated with
UDCA are compared to predicted rates of outcomes based
upon the natural history models applied to a similar population, assuming that they had not been treated with UDCA.35
A Markov model36 has been used to compare survival of
UDCA-treated patients to historical controls using the Mayo
natural history model for PBC. This model predicted a significantly better liver transplant-free survival with UDCA as
compared to the spontaneous survival rate predicted by Mayo
model.36 The overall survival rates without liver transplantation were 84% and 66% at 10 and 20 years, respectively.
In early-stage patients, 6% and 22% were predicted to progress to liver transplantation or death after 10 and 20 years,
respectively.37 On the other hand, the probability of death or
liver transplantation was significantly increased in patients
in late stages of the disease.
However, ~30%–40% of PBC patients show suboptimal
biochemical responses to UDCA or are intolerant to UDCA
and remain at risk for continued progression to advanced
diseases including cirrhosis.26,27 The biochemical response to
UDCA after 1 year of treatment is a strong predictor of longterm clinical outcomes and, thus, is very helpful in identifying the patient population in need for additional therapies.38
Multiple studies have proposed various criteria for improvement in liver biochemistries as predictors of treatment success
with UDCA.39,40 Large cohorts from France and UK showed
that reduction of ALKP to ,1.5 times the ULN and a normal
total bilirubin after 1 year of treatment with UDCA (Paris II
criteria) are associated with excellent long-term survival and
identified patients at low risk for disease progression.40 The
collaboration of multiple international cohorts of .4,500
PBC patients established the PBC GLOBE score which
examined the risk of liver transplantation or death as a
function of serum ALKP and total bilirubin after 1 year of
UDCA treatment.39 The PBC GLOBE score incorporates age
at the time of initiating UDCA therapy, serum ALKP, total
bilirubin, albumin and platelet counts. A recent meta-analysis
evaluated the impact of ALKP and total bilirubin levels on
the long-term outcomes, such as liver transplantation and
death.41 The authors concluded that the 10-year survival
rate without a liver transplant after 1 year of treatment with
UDCA was 84% in patients with ALKP level of #2 times
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the ULN and 86% in patients with bilirubin levels #1 times
the ULN, as compared to 62% in patients with ALKP level
of .2 times the ULN (P,0.0001) and 41% in patients with
bilirubin levels .1 times the ULN (P,0.0001).41

Obeticholic acid
OCA (6α-ethyl-chenodeoxycholic acid) is a selective
farnesoid-X-receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid that has been
modified chemically to make it 100 times more potent than
chenodeoxycholic acid.42,43 The FXR nuclear receptor is
expressed in the liver, intestine, adrenal glands and kidneys;
this nuclear receptor has a significant role in the synthesis
and enterohepatic circulation of the bile acids. FXR activation in the liver reduces the conversion of cholesterol to bile
acids by downregulating cytochrome P450 7A1 (CYP7A1)
and CYP8B1, the primary enzymes involved in the synthesis of bile acids, and increases the expression of bilirubin
exporter pumps. In the ileum, activation of FXR receptor
inhibits the uptake of bile acids by down regulating the
sodium-dependent bile acid transporter and also decreased
the production of bile acids by increasing the expression
of fibroblast growth factor in the liver through inhibition
of CYP7A1.42,44,45 Therefore, OCA increases bile flow in
cholestatic conditions, and thereby protects the hepatocytes
from accumulation of cytotoxic bile acids. In addition,
various preclinical studies have found that OCA also has
antifibrotic and anti-inflammatory properties.45 OCA has
shown improvement in the biochemical markers of liver
function in multiple clinical trials.46–48

Clinical trials
Two major Phase II studies46,47 and a Phase III study48 have
evaluated the safety and efficacy of OCA in patients with
PBC. The summary of OCA clinical trials is presented
in Table 1.
The efficacy of OCA as monotherapy, comparing 10
and 50 mg OCA, was evaluated in a Phase II, international,
double-blind, placebo-controlled trial in patients with PBC
with persistent elevation of ALKP (.1.5–2 times the ULN)
and who had not been taking UDCA for at least 6 months.47
The authors reported significant improvement in ALKP levels
with both doses of OCA (the 10 mg OCA group showed the
greatest decrease in ALKP, from 3.9× ULN to 1.9× ULN) as
compared to placebo. The OCA group also showed significant reduction in the values of GGT, conjugated bilirubin,
C-reactive protein, IgM and tumor necrosis factor-α. Pruritus
was the only main clinical adverse event in the OCA group
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Table 1 Summary of major clinical trials of obeticholic acid in primary biliary cholangitis
Authors

Inclusion criteria

Use of
UDCA

Duration

Primary endpoints

Number
of subjects

Kowdley et al47

ALKP .1.5× the ULN,
No UDCA .6 months

No

12 weeks

% reduction in serum ALKP

ALKP 1.5–10× the ULN

Yes

59
23
20
16
165
38
38
48
41
216
73
70
73

Hirschfield et al46

Nevens et al48

ALKP $1.67× the ULN
and/or TB more than
the ULN to 2× the ULN

Yes

12 weeks

12 months

% reduction in serum ALKP

Serum ALKP of ,1.67× the
ULN (with .15% reduction
from baseline) and
normalization of bilirubin

OCA dose

Primary
endpoints met

Placebo
10 mg
50 mg

+0.4%
45%
38%

Placebo
10 mg
25 mg
50 mg

3%
24%
25%
21%

Placebo
5–10 mg
10 mg

10%
46%
47%

Abbreviations: ALKP, alkaline phosphatase; OCA, obeticholic acid; TB, total bilirubin; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.

as compared to placebo, and was more severe among patients
with higher doses.47
Hirschfield et al46 published a randomized, double-blind,
placebo-controlled trial evaluating the safety and efficacy
of three doses of OCA (10, 25 and 50 mg/day) compared
against placebo and UDCA. The study included patients
with persistent elevation of ALKP of .1.5 times the ULN
on a stable dose of UDCA for at least 6 months. The primary
endpoint of significant reduction in serum ALKP from baseline was met in all three OCA dose groups vs placebo. The
mean relative change in ALKP from baseline was a decrease
of 24%, 25% and 21% for the 10, 25, and 50 mg OCA groups,
respectively, compared with a 3% decrease in the placebo
group. The secondary endpoints including significant reductions in the values of GGT, ALT and AST were also met
across all OCA treatment groups as compared to placebo.
Moreover, OCA groups showed significant improvements
in the inflammatory markers, such as C-reactive protein and
IgM values.46
The authors also performed an open-label extension of
the double-blind trial to evaluate the long-term safety and
efficacy of OCA in patients with PBC.49 A total of 78 patients
were enrolled and 61 patients completed the first year. The
subjects were started on a 10 mg daily dose of OCA and
titrated every 8 weeks to a maximum dose of 50 mg. The
mean final daily dose of OCA at 12 months was 20 mg.
The mean ALKP levels were decreased by 71 U/L (19%) at
the 10 mg OCA dose, with a further decrease of 23 U/L (9%)
after titrating the OCA dose from 10 to 25 mg. However, the
mean ALKP increased by 8 U/L with titration from the 25 to
50 mg dose. The major side effect was dose-related pruritus,
which was reported in 87% of patients.49
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The results from the only Phase III clinical trial of OCA,48
the PBC OCA International Study of Efficacy (POISE),
were the basis for the US Food and Drug Administration’s
approval of OCA in the treatment of PBC patients with
incomplete response to UDCA. POISE is an international,
multicenter, randomized, double-blind, placebo-controlled,
Phase III clinical trial that studied the safety and efficacy
of OCA in PBC patients with an incomplete response to, or
who are unable to, tolerate UDCA.48 An inadequate response
to UDCA was defined as ALKP of $1.67 times the ULN
and/or total bilirubin of more than the ULN but ,2 times
the ULN. Most of the participants had been on UDCA for
at least 12 months and were on a stable dose for at least
3 months prior to enrollment. The primary endpoint was a
composite of ALKP level of ,1.67 times the ULN, with a
reduction of at least 15% from baseline, and a normal total
bilirubin level after 12 months of therapy. Two hundred
and seventeen subjects were randomized to receive either
placebo, 10 or 5 mg of OCA titrated to 10 mg of OCA on
the basis of the side effects and biochemical response at
6 months. If patients had side effects such as severe pruritus or had already met the composite primary endpoint,
their dose was not increased. The median UDCA dose was
15.5 mg/kg/day and 7% of patients were UDCA intolerant.
The composite primary endpoint was met in an intentionto-treat analysis with rates of 10% in the placebo group
compared to 47% in the 10 mg OCA group and 46% in the
dose-titrated 5–10 mg OCA group (P,0.0001 for both intervention groups vs placebo). The mean decrease in ALKP
from baseline was 39% in 10 mg OCA dose group, 33%
in 5–10 mg titrated dose OCA group vs 5% in the placebo
group (P,0.0001 for both intervention groups vs placebo).
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In addition to the improvement in the serum level of ALKP,
patients treated with 5 and 5–10 mg titrated dose had a
greater decrease in total bilirubin compared to placebo
(−0.02 and −0.05, respectively, vs 0.12; P-value for both
OCA dose groups was ,0.001 vs placebo). Moreover, both
the OCA intervention groups met predefined secondary
endpoints including significant improvement of serum
AST, serum ALT, serum GGT and the markers of inflammation (P-value for both OCA dose groups was ,0.0005
vs placebo).48
Ninety-seven percent of the patients who completed
the double-blind phase of the POISE trial entered an openlabel extension phase, which is ongoing and will continue
for a total of 5 years. The subjects who received OCA in
the double-blind trial showed sustained improvements in
ALKP levels; the placebo patients initiating treatment with
OCA showed similar improvements in ALKP and bilirubin
level as compared to the OCA-treated groups in the doubleblind phase.48

Safety and tolerability
Side effects related to OCA were usually mild to moderate
and mostly related to pruritus. Treatment with OCA has been
associated with increase in low-density lipoprotein-cholesterol
and decrease in high-density lipoprotein-cholesterol
(HDL-C) and triglycerides. The clinical significance of
HDL-C reduction in PBC patients is unclear, as the patients
had relatively high levels of HDL-C at baseline. Also, the
absolute differences are relatively small. Other commonly
reported adverse outcomes were fatigue, headache, and
gastrointestinal side effects.46–48

Pruritus
Pruritus is the most common adverse effect in the intervention group requiring change in dose and/or discontinuation
of the treatment. The current evidence suggests that there
is increased frequency and severity of pruritus, especially
in OCA treatment groups at higher doses. Assessment of
pruritus as a side effect in PBC is confounded by the fact that
it is a common symptom in PBC patients. In the randomized
clinical trial conducted by Hirschfield et al,46 the incidence
of pruritus was 50% in the placebo group as compared to
85% in the 25 mg OCA group (P,0.0003), 80% in the
50 mg OCA group (P,0.006) and 47% in the 10 mg OCA
group (P=0.7949). Sixteen percent of patients in the 10 mg,
24% in the 25 mg and 37% in the 50 mg groups discontinued
the trial due to severe pruritus, as compared to 0% in the
placebo group. Overall, 10% of the OCA-treated patients
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discontinued the trial due to pruritus. The similar effects of
OCA related to pruritus were also observed in the POISE
trial.48 The incidence rates of pruritus were 38%, 56% and
68% in the placebo, 5–10 and 10 mg groups, respectively. The
severity of pruritus was less in the titration group (,1% discontinued the trial due to pruritus) as compared to the 10 mg
OCA group (10% discontinued the trial due to pruritus).
Overall, fewer than 6% of OCA-treated patients discontinued
the trial due to pruritus. In the open-label extension phase
with up to 2 years of follow-up, new incidence of pruritus
is 15% in the 5–10 mg group and 21% in the 10 mg group,
which is lower than the double-blind phase.50,51 In summary,
pruritus is the major side effect of OCA in PBC, although
this symptom can be managed in most patients by the use
of bile acid sequestrants, antihistamines, dose reduction or
symptomatic treatment.52

Dyslipidemia
PBC patients with early disease have elevated total cholesterol likely due to high HDL-C levels. Changes in
serum cholesterol levels were observed in clinical trials of
OCA.46–48 Hirschfield et al46 reported changes in the serum
lipid level, especially decrease in HDL and total cholesterol
was observed in the OCA group. A dose-related decrease
in total cholesterol of 3%, 5% and 13% was observed in
the OCA 10, 25 and 50 mg groups, respectively, which was
due to a decrease in HDL levels. There was a decrease in
HDL level in all intervention groups; the mean reduction
in HDL was 8 mg/dL (12%) in the 10 mg OCA group and
9 mg/dL (13%) in both the 25 and 50 mg OCA groups, as
compared to the placebo group that had relatively no change
in HDL. The HDL levels were increased in all intervention
groups during the off-treatment phase, which is suggestive
of the OCA-induced effect on HDL. The POISE trial48 also
observed similar effects of OCA on HDL level. It found
reduction of 16% in the titrated group, 26% in the 10 mg
group and 3% in the placebo group. Additionally, a modest
decrease in triglycerides with no change in low-density
lipoprotein-cholesterol was observed in the OCA-treated
groups. This could be explained by the fact that the elimination of cholesterol is reduced by attenuating hepatic bile
acid synthesis.53 The changes in cholesterol levels are summarized in Table 2.

Other adverse events
Other common side effects that were observed in the treatment groups were headache, rash, and gastrointestinal symptoms such as abdominal discomfort, nausea and vomiting.
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Table 2 OCA clinical trials – absolute change in lipid levels from baseline

LDL-C (mg/dL)
HDL-C (mg/dL)
Triglyceride (mg/dL)

Phase II OCA
Kowdley et al47

Phase II OCA + UDCA
Hirschfield et al46

Phase III OCA ± UDCA
Nevens et al48

Placebo
(n=23)

OCA 10 mg
(n=20)

Placebo
(n=38)

OCA 10 mg
(n=38)

Placebo
(n=73)

Titration OCA
(n=70)

OCA 10 mg
(n=73)

−3.1
−1.5
−1.8

3.9
−12.7
−2.7

3.5
3.5
−8.9

9.7
−9.7
−2.7

1.4
−3.5
4.4

3.5
−11.2
−5.3

−1.9
−16.6
−14.2

Abbreviations: HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; OCA, obeticholic acid; UDCA, ursodeoxycholic acid.

Emerging treatments
The requirement for additional treatment for PBC is clearly
recognized. Multiple noncontrolled studies found significant
improvement in serum ALKP following administration of
fibrates in PBC patients. However, these studies are limited
due to lack of appropriate controls, smaller follow-up and
ill-defined patient population. A Phase III randomized trial
is currently underway. Novel immunologic treatments such
as anti-interleukin-12, anti-CD80, anti-CD20 (rituximab),
mesenchymal stem cells and cytotoxic T-lymphocyte
antigen 4 (abatacept) are currently under investigation for
the treatment of PBC.54–57

Summary
The recent approval of OCA in the treatment of PBC is an
important advance for patients who are at an increased risk
of liver-related complications despite UDCA therapy or
are unable to tolerate UDCA. However, additional data are
awaited to examine the effects of OCA in long-term clinical
outcomes such as quality of life measures, decompensation
of liver disease or liver-related mortality. The major adverse
events related to OCA in PBC are dose-related side effects
and possible negative effects on lipid profiles, although the
clinical significance of this problem in cholestatic liver disease is unknown. A long-term study is underway to determine
whether liver-related outcomes are improved with prolonged
OCA treatment. Meanwhile, it is appropriate for clinicians
to screen their patients with PBC and evaluate whether their
ALKP is 1.67 times the ULN despite UDCA therapy, or in
patients intolerant of UDCA to determine whether they are
appropriate candidates for treatment with OCA.
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